Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Hematology

Building Your Care Team and Preparing for Your First Visit

At a Glance

When preparing for your first Myelodysplastic Syndrome (MDS) appointment, bring physical copies of your full pathology report, genetic tests, and biopsy glass slides. Ensure your hematologist specializes in MDS and uses the IPSS-M molecular scoring system to guide your treatment.

MDS is a complex and highly specialized field. Because the biology of the disease and the treatment options are changing so rapidly, who you have on your team is just as important as the diagnosis itself.

Think of this first visit as a “job interview” where you are hiring the experts who will guide you through this journey.

Building Your Roster

A complete care team for MDS is multidisciplinary, meaning it includes experts from several different areas of medicine [1][2].

  • MDS Specialist (Hematologist-Oncologist): This is your team leader. They should focus specifically on blood cancers and be familiar with the 2022 WHO and ICC classification standards [3][4].
  • Transplant Specialist: Even if you are not ready for a transplant now, meeting with a transplant physician early is essential for intermediate or high-risk patients. A transplant is currently the only potential cure, and you want to have a plan in place before you need it [5][2].
  • Hematopathologist: This is the doctor you may never meet, but they are the ones who look at your bone marrow under a microscope. Their expertise is vital for distinguishing MDS from conditions that mimic it [6][4].
  • Specialized Nurse or Navigator: These professionals help you manage daily symptoms, schedule complex tests, and find emotional support [7].

Your First Visit Checklist

To get the most out of your first specialist visit, you must bring your “physical artifacts.” Do not rely on hospitals to send records to each other; having them in your hand ensures your appointment is productive [8][9].

Essential Records to Bring:

  • Full Pathology Report: The detailed, multi-page report from your bone marrow biopsy (not just a summary) [3].
  • Cytogenetics/Karyotype Report: The test results showing your chromosome structure [8].
  • NGS Genetic Panel: The results from your Next-Generation Sequencing (molecular) test [10].
  • Glass Slides: If you are seeking a second opinion, you must request the actual glass slides and paraffin blocks of your bone marrow from the hospital where the biopsy was performed. The new specialist’s pathologist will want to look at them directly [4].

Vetting Your Doctor’s Expertise

Not every hematologist is an MDS expert. Use these questions to help determine if your doctor has the specialized knowledge required for this disease [3][11]:

  1. “Do you use the IPSS-M (Molecular) score to determine my risk?” An expert should be using the molecular score rather than just the older IPSS-R to provide a more accurate prognosis [11].
  2. “How does my specific genetic mutation (e.g., TP53 or SF3B1) affect my treatment?” This tests whether the doctor understands the latest molecularly targeted treatment options [12].
  3. “What clinical trials do you have available for my subtype of MDS?” Access to clinical trials is a hallmark of an expert center [12].

Common questions in this guide

What doctors should be on my MDS care team?
Your core team should include a hematologist-oncologist who specifically focuses on blood cancers, a transplant specialist, a hematopathologist to review your bone marrow biopsies, and a specialized nurse navigator.
What records should I bring to my first MDS appointment?
You should bring physical copies of your full bone marrow pathology report, cytogenetics or karyotype results, Next-Generation Sequencing (NGS) genetic panel, and the actual glass slides from your biopsy if you are seeking a second opinion.
Why do I need to see a transplant specialist for MDS?
Even if you do not need a transplant right away, consulting a specialist early is important for intermediate or high-risk patients. A stem cell transplant is currently the only potential cure, so having a plan in place early is essential.
What is the IPSS-M score and why is it important?
The IPSS-M is the Molecular International Prognostic Scoring System. An MDS expert should use this newer score rather than older systems because it incorporates your specific genetic mutations to provide a more accurate prognosis and treatment plan.
How do I know if my hematologist is an MDS expert?
You can assess their expertise by asking how many new MDS patients they treat each year, if they use the IPSS-M scoring system, and whether they offer clinical trials for your specific genetic subtype, such as SF3B1 or del(5q).

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are you using the IPSS-M (Molecular) system to determine my risk score?
  2. 2.How many new patients with MDS do you personally treat every year?
  3. 3.Do you have a dedicated hematopathologist on-site who specializes in reading bone marrow biopsies?
  4. 4.What is your institution's approach to clinical trials, and are there any open specifically for my genetic subtype (like SF3B1 or del(5q))?
  5. 5.At what point in my care do you typically involve a stem cell transplant specialist?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.

    Kewan T, Stahl M, Bewersdorf JP, Zeidan AM

    Current hematologic malignancy reports 2024; (19(3)):138-150 doi:10.1007/s11899-024-00733-y.

    PMID: 38632155
  2. 2

    Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

    de Witte T, Bowen D, Robin M, et al.

    Blood 2017; (129(13)):1753-1762 doi:10.1182/blood-2016-06-724500.

    PMID: 28096091
  3. 3

    Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.

    Maggioni G, Della Porta MG

    Current opinion in hematology 2023; (30(2)):30-37 doi:10.1097/MOH.0000000000000752.

    PMID: 36728601
  4. 4

    Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.

    Lee WH, Lin CC, Tsai XC, et al.

    Blood cancer journal 2024; (14(1)):57.

    PMID: 38594285
  5. 5

    Advances in the management of higher-risk myelodysplastic syndromes: future prospects.

    Gener-Ricos G, Rodriguez-Sevilla JJ, Urrutia S, et al.

    Leukemia & lymphoma 2024; (65(9)):1233-1244 doi:10.1080/10428194.2024.2344061.

    PMID: 38712556
  6. 6

    Where Does Morphology Fit in Myelodysplastic Syndrome Diagnosis in the Era of Molecular Testing?

    Giagounidis A, Haase S

    Hematology/oncology clinics of North America 2020; (34(2)):321-331 doi:10.1016/j.hoc.2019.11.005.

    PMID: 32089213
  7. 7

    Understanding the evolving role of early palliative care in myelodysplastic syndromes: a 2026 narrative review.

    Niscola P, Gianfelici V, Giovannini M, et al.

    Annals of hematology 2026; (105(5)).

    PMID: 42081107
  8. 8

    Computational flow cytometry as a diagnostic tool in suspected-myelodysplastic syndromes.

    Duetz C, Van Gassen S, Westers TM, et al.

    Cytometry. Part A : the journal of the International Society for Analytical Cytology 2021; (99(8)):814-824 doi:10.1002/cyto.a.24360.

    PMID: 33942494
  9. 9

    Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?

    Sangiorgio VFI, Orazi A, Arber DA

    Best practice & research. Clinical haematology 2020; (33(2)):101139 doi:10.1016/j.beha.2019.101139.

    PMID: 32460987
  10. 10

    Risk stratifying MDS in the time of precision medicine.

    Cazzola M

    Hematology. American Society of Hematology. Education Program 2022; (2022(1)):375-381 doi:10.1182/hematology.2022000349.

    PMID: 36485160
  11. 11

    Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.

    Lee WH, Tsai MT, Tsai XC, et al.

    Blood cancer journal 2023; (13(1)):120.

    PMID: 37558665
  12. 12

    Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy.

    Aleshin A, Greenberg PL

    Blood advances 2018; (2(20)):2787-2797 doi:10.1182/bloodadvances.2018015834.

    PMID: 30352953

This page provides guidance on preparing for an MDS specialist visit for educational purposes. It does not replace professional medical advice from your healthcare team.

Get notified when new evidence is published on Myelodysplastic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.